Real-world TriNetX analysis explores GLP-1 Receptor Agonist and SGLT2 Inhibitor combination therapy for heart failure outcomes
Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis
Abstract
A real-world TriNetX analysis investigates the clinical outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor combination therapy in patients with heart failure.